Latest news with #Cipher
Cision Canada
a day ago
- Business
- Cision Canada
Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue
(All figures are presented in U.S. Dollars) Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025 Adjusted EBITDA 1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024 Epuris sales volumes grew 14% in the quarter compared to Q2 2024 Natroba TM sales were $7.8 million during the quarter, a sequential increase of 16% over Q1 2025 Strong cash generation with $6.0 million cash from operations in Q2 2025 $15.0 million debt repayment and share repurchases of $2.1 million during Q2 2025 $7.0 million debt repayment subsequent to Q2 2025 MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher" or the " Company") today announced its financial and operating results for the three and six months ended June 30, 2025. First Quarter 2025 Financial Highlights (All figures in U.S. dollars, compared to Q2 2024, unless otherwise noted) Total revenue was $13.4 million in Q2 2025, an increase of 152% Canadian product portfolio revenue increased by 12% to $4.1 million in Q2 2025, compared to $3.7 million in Q2 2024 Natroba TM provided $7.8 million of incremental product revenue in Q2 2025 Licensing revenue was $1.5 million in Q2 2025, compared to $1.6 million in Q2 2024 Total gross profit from operations increased by 159% to $10.9 million in Q2 2025 Adjusted EBITDA 1 increased 148% to $7.6 million in Q2 2025 Cash balance of $11.3 million at the end of Q2 2025 Management Commentary Craig Mull, Interim CEO, commented:"Cipher has continued its growth during the second quarter of 2025, with quarterly revenue achieving a historical record for the Company, largely contributed to by our U.S. business. The U.S. business, led by Natroba™, continues to exceed our expectations from when we acquired the business almost one year ago, in July 2024. The U.S. business has contributed to a more than doubling of Cipher's total revenue and Adjusted EBITDA 1 compared to the prior year, for both the second quarter and the year-to-date. We look forward to providing further updates on the impact our strategy and activities surrounding the business have on the performance of Natroba™ for the remainder of 2025. Cipher's base business in Canada continues to experience year-over-year growth from Epuris®, with the product realizing revenue growth of 25% for the year-to-date 2025 compared to the same period in 2024, which largely offsets the decline in revenue derived from our licensing portfolio as a result of the competitive pressures faced by our commercial partners for these out-licensed products in the U.S. market." Ryan Mailling, CFO, commented: "In Q2 2025, we had another quarter of strong cash generation, with $6.0 million of cash generated from operations during the quarter. Cash generated in the second quarter, combined with previous cash accumulation, was allocated during the quarter to a $15.0 million repayment on our revolving credit facility, de-levering the business, as well as repurchases of our common shares through our normal course issuer bid ("NCIB"), which returned $2.1 million to our shareholders. After this effective use of available capital, at the end of the second quarter $11.3 million of cash remained on our balance sheet. Accordingly, subsequent to the end of the quarter we further allocated $7.0 million to an additional repayment on our revolving credit facility, resulting in $47.0 million of financing remaining available through the facility, plus a $25.0 million accordion option, which in total is $72.0 million of total potential financing available. We continue to be in an excellent position to execute on growth opportunities." Corporate Highlights On April 29, 2025, Cipher announced its product Natroba TM received preferred step-through status on Medicaid in the state of Illinois, whereby its main product competitor Permethrin 5% was downgraded to non-preferred on the state's preferred drug listing. This move by Illinois Medicaid will require all prescriptions for Permethrin 5% to first 'step-though' Natroba TM representing the treatment of choice in the state. On May 1, 2025, Cipher announced that the Toronto Stock Exchange (the "TSX") had approved the Company's Notice of Intention to Make a Normal Course Issuer Bid under which the Company may purchase for cancellation, from time to time up to May 4, 2026, up to an aggregate of 1,485,260 of its issued and outstanding common shares, being 10% of its public float of 14,852,604 common shares as of April 22, 2025. In accordance with TSX rules, any daily repurchases on the TSX under the NCIB are limited to a maximum of 10,427 common shares, which represents 25% of the average daily trading volume on the TSX of 41,708 for the six months ended March 31, 2025. To facilitate larger repurchases, the Company is entitled to make one weekly block purchase on the TSX that may exceed the daily repurchase restrictions. On May 8, 2025, the Company repaid $15.0 million of the outstanding balance on its revolving credit facility. On August 6, 2025, the Company repaid $7.0 million of the remaining outstanding balance on its revolving credit facility. As a result of the repayment, the outstanding balance on the Company's revolving credit facility has been reduced to $18.0 million. Due to the revolving nature of the credit facility, an additional $47.0 million remains available to the Company to draw upon, should financing be required. Q2 2025 Financial Review (All figures in U.S. dollars, compared to Q2 2024, unless otherwise noted) Total revenue was $13.4 million in Q2 2025, compared to $5.3 million in Q2 2024, an increase of 152% Product revenue from the Canadian product portfolio was $4.1 million in Q2 2025, an increase of 12% from $3.7 million in Q2 2024 Product revenue from Natroba TM in the U.S. was $7.8 million, up sequentially from $6.7 million in Q1 2025 Licensing revenue decreased 9% to $1.5 million in Q2 2025 compared to $1.6 million in Q2 2024, impacted by lower net sales realized by Cipher's partners on which the Company earns a royalty and contractual royalty rate reductions, partially offset by higher product shipments to licensing partners Total gross profit was $10.9 million in Q2 2025, compared to $4.2 million in Q2 2024, an increase of 159% Gross margin as a percentage of product revenue increased by 9% to 79% in Q2 2025 from 70% in Q2 2024, driven by the addition of Natroba™, which was acquired on July 29, 2024 Total gross margin increased by 2% to 81% in Q2 2025 from 79% in Q2 2024 due to the addition of Natroba™, partially offset by reduced licensing revenue Net income and earnings per common share were $5.9 million and $0.23, respectively, in Q2 2025, compared to $3.0 million and $0.12, respectively, in Q2 2024, with the increase primarily attributable to the additional operating income generated from Natroba™ in Q2 2025 EBITDA 1 in Q2 2025 was $8.6 million, compared to $2.2 million in Q2 2024, an increase of 290% Adjusted EBITDA 1 in Q2 2025 was $7.6 million, compared to $3.1 million in Q2 2024, an increase of $4.5 million or 148% Adjusted EBITDA 1 per share in Q2 2025 was $0.29 compared to $0.13 in Q2 2024, an increase of $0.16 per share or 123% Under the Company's NCIB, 230,278 common shares were repurchased and cancelled at an average share price of CDN$12.74 Business Strategy & Outlook Cipher expects to continue to execute on its business strategy, remains focused on profitability and delivering shareholder value. Key areas of focus include: Driving market share growth of Natroba™ in the anti-parasitic market in the U.S. where market leader "Permethrin" is no longer an effective treatment but still holds 75% 2 market share. Obtaining Health Canada regulatory approval for Natroba™ and commercializing the product directly in the Canadian market by leveraging Cipher's existing infrastructure in Canada. Out-licensing Natroba™ globally where there is high unmet need, such as warm climate regions. Acquiring complementary dermatology products to add to our North American platform to enhance the profitability, size and scale of the business. Financial Statements and MD&A Cipher's financial statements for the three and six months ended June 30, 2025, and Management's Discussion and Analysis (the "MD&A") for the three and six months ended June 30, 2025, are available on the Company's website at in the "Investors" section under "Financial Reports" and on SEDAR+ at Notice of Conference Call Cipher will hold a conference call on August 8, 2025 at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial (416) 945-7677 or (888) 699-1199 A live audio webcast will be available at An archived replay of the webcast will be available until August 15, 2025 and can be accessed by dialing (289) 819-1450 or (888) 660-6345 and entering conference replay code 36094# About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit Forward-Looking Statements and Non-IFRS Measures This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, expectations for future growth, objectives and goals and strategies to achieve those objectives and goals, the potential purchases to be made under the NCIB, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; the extent and impact of health pandemic outbreaks on our business; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process by regulators which can be highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the Company's performance depends, in part, on the performance of its distributors and suppliers; the pharmaceutical industry is highly competitive with new competing product entrants; requirements for additional capital to fund future operations; products may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; the ability to receive regulatory approvals for products in development or future products; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; the ability to convince public payors and hospitals to include our products on the approved formulary lists; ability to receive timely payment from certain customers; application of various laws pertaining to health care fraud and abuse; the Company's reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the healthcare industry generally; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; success in applying tax loss carry forwards; inability to meet covenants under our long-term debt arrangement; compliance with privacy and security regulation; our policies regarding product returns, allowances and chargebacks may reduce revenues; additional regulatory burden and controls over financial reporting; application of regulations that could restrict our activities and abilities to generate revenues as planned; reliance on third parties to perform distribution, logistics, invoicing, regulatory and sales services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; increases in tariffs, trade restrictions or taxes on our products; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up. We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the "Risk Factors" section of our MD&A for the year ended December 31, 2024 and the Company's Annual Information Form, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language. 1) EBITDA and adjusted EBITDA are non-IFRS financial measures. These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are unlikely to be comparable to similar measures presented by other companies. Management uses non-IFRS measures such as Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA to provide investors with supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. The Company defines Adjusted EBITDA as earnings before interest expense, income taxes, depreciation of property and equipment, amortization of intangible assets, non-cash share-based compensation, changes in fair value of derivative financial instruments, costs and provisions for legal matters, loss on disposal of assets and loss on extinguishment of lease, impairment of intangible assets, acquisition costs, restructuring costs, fair value adjustments to acquired inventory and unrealized foreign exchange gains and losses. 2) IQVIA market data as at June 30, 2025. The following is a summary of how EBITDA and Adjusted EBITDA are calculated: (IN THOUSANDS OF U.S. DOLLARS, Three months ended June 30, 2025 Three months ended June 30, 2024 Six months ended June 30, 2025 Six months ended June 30, 2024 except for per share amounts) $ $ $ $ Net income and comprehensive income 5,893 2,995 8,517 7,918 Add back: Depreciation and amortization 1,807 292 3,629 581 Interest expense (income) 345 (611) 815 (1,166) Income tax expense (recovery) 512 (480) (225) (2,435) EBITDA 8,557 2,196 12,736 4,898 Unrealized foreign exchange (gain) loss (1,759) 401 (1,770) 1,043 Acquisition, restructuring and other costs — 284 128 284 Fair value adjustments to acquired inventory 131 — 777 — Costs and provisions for legal matter 221 — 1,221 — Share-based compensation 436 183 680 407 Adjusted EBITDA 7,586 3,064 13,772 6,632 Adjusted EBITDA per share – basic 0.29 0.13 0.54 0.28 Adjusted EBITDA per share – dilutive 0.29 0.12 0.52 0.27 Consolidated statements of income and comprehensive income Three months ended June 30, Six months ended June 30, (IN THOUSANDS OF U.S. DOLLARS, 2025 2024 2025 2024 except for per share amounts) $ $ $ $ Revenue Licensing revenue 1,478 1,618 2,213 4,218 Product revenue 11,903 3,686 23,187 6,953 Net revenue 13,381 5,304 25,400 11,171 Operating expenses Cost of products sold 2,498 1,106 5,377 2,161 Research and development — — 21 — Depreciation and amortization 1,807 292 3,629 581 Selling, general and administrative 4,085 1,601 9,036 3,069 Total operating expenses 8,390 2,999 18,063 5,811 Other (income) expenses Interest expense (income) 345 (611) 815 (1,166) Unrealized foreign exchange (gain) loss (1,759) 401 (1,770) 1,043 Total other (income) expenses (1,414) (210) (955) (123) Income before income taxes 6,405 2,515 8,292 5,483 Current income tax expense — — — — Deferred income tax expense (recovery) 512 (480) (225) (2,435) Total income tax expense (recovery) 512 (480) (225) (2,435) Net income and comprehensive income for the period 5,893 2,995 8,517 7,918 Income per share Basic 0.23 0.12 0.33 0.33 Diluted 0.22 0.12 0.32 0.32 Consolidated statements of financial position As at June 30, As at December 31, 2025 2024 (IN THOUSANDS OF U.S. DOLLARS) $ $ Assets Current assets Cash and cash equivalents 11,339 17,837 Accounts receivable 11,868 13,860 Inventory 5,576 5,792 Prepaid expenses and other assets 1,766 995 Total current assets 30,549 38,484 Property and equipment 522 680 Intangible assets 75,287 78,754 Deferred financing costs 311 386 Goodwill 17,447 17,447 Deferred tax assets 28,278 26,761 Total assets 152,394 162,512 Liabilities and shareholders' equity Current liabilities Accounts payable and accrued liabilities 4,846 5,873 Income taxes payable 9 54 Interest payable 82 358 Contract liabilities 12,564 13,306 Current portion of lease obligation 262 283 Total current liabilities 17,763 19,874 Lease obligation 193 295 Long-term debt 25,000 40,000 Total liabilities 42,956 60,169 Shareholders' equity Share capital 27,556 27,680 Contributed surplus 7,149 6,525 Accumulated other comprehensive loss (9,514) (9,514) Retained earnings 84,247 77,652 Total shareholders' equity 109,438 102,343 Total liabilities and shareholders' equity 152,394 162,512 SOURCE Cipher Pharmaceuticals Inc.
Cision Canada
29-07-2025
- Business
- Cision Canada
Cipher Pharmaceuticals Schedules Q2 2025 Earnings Release and Conference Call
MISSISSAUGA, ON, July 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher" or the " Company") today announced that it will release its financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The Company will also hold a conference call on Friday, August 8, 2025 at 8:30am ET to discuss the results and corporate developments. CONFERENCE CALL DETAILS About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit SOURCE Cipher Pharmaceuticals Inc.
Business Upturn
23-07-2025
- Entertainment
- Business Upturn
Gen V Season 2: Latest cast updates, plot details and release date
By Aman Shukla Published on July 23, 2025, 19:43 IST Last updated July 23, 2025, 19:47 IST If you loved the bloody chaos, biting satire, and campus madness of Gen V , get ready — Season 2 is on the way, and it's bigger, darker, and more intense. The Boys spin-off made serious waves with its first season, and now fans are counting down the days until the next round at Godolkin University. Gen V Season 2 Release Date Gen V Season 2 premieres on September 17, 2025, on Amazon Prime Video, kicking off with a three-episode drop. After that, new episodes will stream weekly every Wednesday, wrapping up with the finale on October 22, 2025. Season 1 dropped a little later in the year (Sept 29, 2023), so this one's coming a bit earlier — and yes, filming is already wrapped as of November 2024. Gen V Season 2 Cast Updates Most of your favourites from Season 1 are back, along with some intriguing new additions. Returning cast: Jaz Sinclair as Marie Moreau , still mastering her bloody powers in a now militarized Godolkin. Lizze Broadway as Emma Meyer , struggling with her identity and trauma. Maddie Phillips as Cate Dunlap , now one of Godolkin's so-called heroes. London Thor & Derek Luh as Jordan Li , the gender-shifting Supe facing fresh challenges. Asa Germann as Sam Riordan , trying to stay sane in a broken system. Sean Patrick Thomas returns as Polarity , with a storyline honoring his on-screen son Andre. New faces: Hamish Linklater joins as Cipher , the new dean — mysterious, intense, and clearly not here to nurture students. Plus a whole lineup of new characters played by Keeya King, Stephen Kalyn, Julia Knope, Stacey McGunnigle, Tait Fletcher, Wyatt Dorion, and Georgie Murphy. Not returning: Sadly, Chance Perdomo (Andre) passed away in 2024. His character won't be recast, and the season's been reworked to honor him. Patrick Schwarzenegger (Golden Boy) is out — both because of his character's death and his work on The White Lotus Season 3. Shelley Conn (Indira Shetty) won't return either — she didn't survive Season 1. Cameos to look for: Chace Crawford returns as The Deep from The Boys , tightening the crossover. Valorie Curry reprises her role as Firecracker , continuing the shared-universe threads. What To Expect in Gen V Season 2 Season 2 kicks off after the wild ending of The Boys Season 4. Godolkin University isn't the same anymore — it's now training Supes as soldiers under the watch of Dean Cipher. Marie, Emma, and Jordan return to campus, mentally scarred and walking into a very different world. Meanwhile, Cate and Sam have become media darlings — the so-called 'Guardians of Godolkin.' There's a lot going on: Homelander's influence is creeping in, Vought's grip is tightening, and a hidden program tied to the university's origins could change everything. Expect more power games, moral gray zones, and the kind of madness only The Boys universe can deliver. Showrunner Michele Fazekas is back to lead the charge, with The Boys creator Eric Kripke teasing this season as the 'first glimpse into the new world' following Season 4's fallout. Oh, and yes — keep an eye out for possible cameos from other Supes (looking at you, Zoey Neuman). Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Insider
18-07-2025
- Business
- Business Insider
Canaan to produce A15Pro Miners for Cipher Mining
Canaan's (CAN) U.S. subsidiary has entered into a purchase agreement with Cipher Mining (CIFR) to supply approximately 6,840 Avalon A15Pro miners to Cipher's Black Pearl facility in Q3. The units will be fulfilled by Canaan's U.S. and Malaysian facilities. This agreement marks Canaan's first major initiative to offer large-scale domestic manufacturing support for U.S.-based bitcoin mining customers. The miners are expected to be deployed at Cipher's Black Pearl facility. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Time of India
01-07-2025
- Entertainment
- Time of India
Where to find every Hunter Mask in Division 2 Battle for Brooklyn DLC
(Image via Ubisoft) Division 2: Battle for Brooklyn DLC is full of cryptic challenges. Elite hunters here guard unique masks all across the new urban battleground, and they reward it to players, for defeating them. To unlock these coveted masks requires more than just firepower. It demands players to be keen on observation and to have some puzzle-solving skills. So, be prepared to explore Brooklyn Heights and much beyond while deciphering some environmental clues under specific conditions. Here is complete Division 2 masks guide to how you can track and hunt each of them that remains shrouded in mystery. All Hunter Masks in Division 2: Battle for Brooklyn DLC To find all Division 2 Hunter Masks in Brooklyn includes tackling distinct and location-based puzzles. Every mask—Cipher, Conqueror, Craver, Lumen, Merry, Necronos, Redtail, and Tracker needs to be triggered by a specific Hunter through some unique actions. So, expect to explore areas including the waterfront near the carousel for Merry. Make sure you complete 7 parts of the wooden horse that's scattered all across the map to spawn the hunter. Investigate buildings with some unusual features (letters on them), near the Brooklyn Bridge, and shoot letters for spelling ROBOTO, for Cipher. How to UNLOCK ALL 8 HUNTER MASK in Battle for Brooklyn DLC for the Division 2! (UPDATED GUIDE) For Tracker head to one of Dumbo's building near the central point follow zigzag motion and then rise lever for spawning hunter. On the other hand, for Craver, interact with the gas cylinders across the map. There are 4 in total, and as you collect them, head to the Brooklyn Heights Waterfront to interact with cylinders piled up on a boat. Ensure to have precision as its paramount. Your actions here will range from shooting some specific targets to assembling scattered objects or even interacting with hidden switches, quite often tied to a particular time of day. Lumen requires solving one of the Hunter Mask puzzles and it will start under the Brooklyn Bridge at night and demand that players follow blacklight graffiti. It will lead you to the hunter. Missing a step or performing actions that are not in sequence would likely result in failure. The agent must therefore thoroughly follow all cues that are discovered via exploration. For Redtail, interact with and disable different antennas all across the Brooklyn map. Then locate the underground lair of the hunter in Dumbo, deactivate the system and return out for spawning. Meanwhile, for Conqueror, all stuffed animals should be detonated. Once all 7 are detonated, head to Furman Street's Brooklyn Heights and find a stuffed monkey with many toys right beside it. Interact to spawn a hunter. Lastly, for Necronos to be spawned, all the previous hunter riddles attempted must be spawned. Once done, head to Dumbo, find Division 1 (west of Brooklyn safe house), interact with the whiteboard and head to the house's roof to fight the hunter and claim your reward. Collect rewards for being a persistent hunter Defeat all formidable foes and yield more than just the bragging rights. All hunters drop the Ash Cache key right along with their unique mask. Collect all eight keys and unlock access to the special Ash Cache that's located within the Bridge settlement. It holds the ultimate price—the Huntsman assault rifle. It is exclusive to DLC. R emember, the Huntsman comes equipped with some powerful and perfect frenzy talent. It boosts the rate of fire as well as weapon damage when reloading from empty. It alone can make conquering all 8 Hunter encounters worth it. Once it is unlocked, Cassie Mendoza might even offer some additional Huntsman rolls for further customization. Best Division 2 gameplay strategies for defeating all Hunters Hunters are the toughest enemies in Brooklyn. They use aggressive tactics, heal themselves, disrupt agent skills, and use some advanced tech, including cloaking. Here, success demands the right preparation. Lowering the world's difficulty for normal will ease the combat challenge without any impact on mask acquisition. Give priority to protection from Elite gear mods for mitigating heavy damage. Effective crowd control here is crucial. So, use gears/weapons that inflict status effects, including foam or shock, for immobilization momentarily. Keep focus on high burst damage builds for exploiting windows. Coordination in a team will significantly improve survival chances via focused fire and also revives. Just remember, skills are often disabled during fights. Now that you know how to find Hunter Masks, just rely on your positioning and gunplay. With the right prep and patience, you will be able to claim all the masks and prove dominance within Brooklyn's darkest corners. Happy hunting! Game On Season 1 continues with Mirabai Chanu's inspiring story. Watch Episode 2 here.
